JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer

  • 0Department of Medicine, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.
Biomarker Insights +

|

March 1, 2024

|

March 1, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Detecting methylated circulating tumor DNA (ctDNA) before treatment can improve recurrence prediction in colorectal cancer (CRC) patients, especially those with perineural invasion. This biomarker enhances traditional prognostic factors for better disease management.

Area Of Science

  • Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background

  • Colorectal cancer (CRC) recurrence rates are high, particularly for advanced stages.
  • Current prognostic methods based on staging and pathology have limitations in predicting recurrence.
  • Circulating tumor DNA (ctDNA) at diagnosis shows potential for improving recurrence prediction.

Purpose Of The Study

  • To evaluate the predictive value of methylated <i>BCAT1/IKZF1</i> ctDNA at diagnosis for CRC recurrence.
  • To assess the combined impact of ctDNA with demographic, lifestyle, clinical factors, and tumor pathology.
  • To determine if ctDNA improves recurrence prediction beyond established prognostic indicators.

Main Methods

  • Retrospective cohort study of 180 patients with a minimum 3-year follow-up.
  • Analysis of pre-treatment plasma samples for methylated <i>BCAT1/IKZF1</i> ctDNA.
  • Cox regression analysis to assess factors associated with disease-free survival.

Main Results

  • Nodal involvement, M1 stage, resection margin <2mm, perineural involvement, and distal tumors were independently associated with reduced disease-free survival.
  • Methylated <i>BCAT1/IKZF1</i> was detected in 51.7% of pre-treatment samples.
  • Combining ctDNA with clinical factors improved recurrence prediction for perineural involvement, M1 stage, and distal tumors.

Conclusions

  • Clinical factors like nodal invasion and perineural invasion are significant predictors of CRC recurrence.
  • Pre-treatment methylated ctDNA measurement enhances the predictive value for recurrence in specific patient subsets.
  • ctDNA testing offers a promising tool to refine prognostication and guide management in colorectal cancer.

Keywords: